In Vitro Analysis of the Effects of ITER-Like Tungsten Nanoparticles: Cytotoxicity and Epigenotoxicity in BEAS-2B Cells.
BEAS-2B cells.
DNA damage
DNA methylation
cytotoxicity
epigenetics
in vitro testing
micronuclei formation
nanoparticles
tritiated particles
tungsten
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
30 Aug 2019
30 Aug 2019
Historique:
received:
26
07
2019
revised:
22
08
2019
accepted:
26
08
2019
entrez:
5
9
2019
pubmed:
5
9
2019
medline:
5
9
2019
Statut:
epublish
Résumé
Tungsten was chosen as a wall component to interact with the plasma generated by the International Thermonuclear Experimental fusion Reactor (ITER). Nevertheless, during plasma operation tritiated tungsten nanoparticles (W-NPs) will be formed and potentially released into the environment following a Loss-Of-Vacuum-Accident, causing occupational or accidental exposure. We therefore investigated, in the bronchial human-derived BEAS-2B cell line, the cytotoxic and epigenotoxic effects of two types of ITER-like W-NPs (plasma sputtering or laser ablation), in their pristine, hydrogenated, and tritiated forms. Long exposures (24 h) induced significant cytotoxicity, especially for the hydrogenated ones. Plasma W-NPs impaired cytostasis more severely than the laser ones and both types and forms of W-NPs induced significant micronuclei formation, as shown by cytokinesis-block micronucleus assay. Single DNA strand breaks, potentially triggered by oxidative stress, occurred upon exposure to W-NPs and independently of their form, as observed by alkaline comet assay. After 24 h it was shown that more than 50% of W was dissolved via oxidative dissolution. Overall, our results indicate that W-NPs can affect the in vitro viability of BEAS-2B cells and induce epigenotoxic alterations. We could not observe significant differences between plasma and laser W-NPs so their toxicity might not be triggered by the synthesis method.
Identifiants
pubmed: 31480309
pii: nano9091233
doi: 10.3390/nano9091233
pmc: PMC6780084
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : A*MIDEX
ID : ANR-11-IDEX-0001-02
Références
Chem Res Toxicol. 1995 Jun;8(4):600-6
pubmed: 7548741
Int J Nanomedicine. 2011;6:167-78
pubmed: 21499416
J Appl Toxicol. 2018 Jun;38(6):896-913
pubmed: 29405315
Mol Carcinog. 2017 Jul;56(7):1778-1788
pubmed: 28218462
Toxicol Appl Pharmacol. 2011 Jun 15;253(3):178-87
pubmed: 21513724
Toxicol Sci. 2015 Feb;143(2):385-97
pubmed: 25398624
Mutagenesis. 2011 Jan;26(1):185-91
pubmed: 21164201
IARC Monogr Eval Carcinog Risks Hum. 2006;86:1-294
pubmed: 16906675
Sci Total Environ. 1997 Nov 5;206(2-3):147-65
pubmed: 9394480
Environ Health Perspect. 2009 Apr;117(4):530-6
pubmed: 19440490
Toxicol Appl Pharmacol. 2015 Oct 1;288(1):33-9
pubmed: 26164860
J Immunotoxicol. 2010 Jul-Sep;7(3):174-82
pubmed: 20178456
Toxicol Appl Pharmacol. 2014 Jul 1;278(1):1-8
pubmed: 24746988
Toxicol Sci. 2014 Jan;137(1):125-34
pubmed: 24085191
Part Fibre Toxicol. 2016 Feb 03;13:5
pubmed: 26843362
Pharm Sci Technolo Today. 2000 Jan;3(1):18-27
pubmed: 10637597
Nucleic Acids Res. 2019 Apr 8;47(6):2822-2839
pubmed: 30698748
Drug Metab Dispos. 2012 Oct;40(10):1953-65
pubmed: 22798553
Nat Protoc. 2007;2(5):1084-104
pubmed: 17546000